Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983263 | 0.77 | USP2 (0.46) | MAPTUSP2PAK1HPRT1MEN1 | |
| SCHEMBL19063379 | 0.77 | USP2 (0.46) | MAPTUSP2PAK1HPRT1MEN1 | |
| SCHEMBL19091475 | 0.76 | NMUR2 (0.38) | DNMT1HPRT1 | |
| SCHEMBL19082475 | 0.76 | CYP1A1 (0.35) | DNMT1MAPTHPRT1MEN1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28881581 | 0.76 | USP2 (0.44) | MAPTUSP2PAK1HPRT1MEN1 | |
| SCHEMBL29983226 | 0.76 | USP2 (0.44) | MAPTUSP2PAK1HPRT1MEN1 | |
| SCHEMBL19082467 | 0.76 | MAPT (0.41) | DNMT1MAPTMEN1ALDH1A1RAB9A | |
| SCHEMBL19077625 | 0.75 | KDM4E (0.33) | MAPTMEN1KMT2A | |
| SCHEMBL19082498 | 0.70 | MEN1 (0.40) | DNMT1MAPTSLC22A12HPRT1MEN1 | |
| SCHEMBL19901855 | 0.70 | CYP2A6 (0.44) | MAPTUSP2PAK1HPRT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | DNMT1 876/4885MAPT 1294/4885SLC22A12 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.